

Chuanhu anti-gout mixture in therapy of acute gouty arthritis

Submission date 05/07/2013	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 08/08/2013	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 17/12/2020	Condition category Musculoskeletal Diseases	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Chuanhu anti-gout mixture has been used for many years for treating gout in Chinese Traditional Medicine (TCM), while current standards for treatments for acute gouty arthritis (such as anti-inflammatory drugs [NSAIDs], colchicine and corticosteroids) were either less effective or had serious side-effects. The present study was designed to test the effectiveness of Chuanhu anti-gout mixture for therapy of acute gouty arthritis compared to colchicines.

Who can participate?

Adults with a new clinical diagnosis of gout and onset of the disease duration less than 48 hours were eligible to participate.

What does the study involve?

The participants were randomly allocated to one of the two groups:

Chuanhu group: to receive Chuanhu anti-gout mixture orally daily and placebo (dummy).

Colchicine group: to receive Colchicine 1 piece orally two times daily, for 3 days, later change to once daily, and placebo (dummy).

All of the patients were treated with etoricoxib 60 mg once daily orally to relieve pain of the affected joints for 10 days.

What are the possible benefits and risks of participating?

Chuanhu anti-gout mixture might be effective for therapy of acute gouty arthritis, and have fewer side-effects compared to colchicine. The possible risks include the adverse reactions pain, swelling and activity limitation of the joint, together with injury/damage to the liver and kidney.

Where is the study run from?

The study was run in the Affiliated Hospital of Qingdao University Medical College, Qingdao, China.

When is the study starting and how long is it expected to run for?

The study started in November 2011 and ran until November 2012.

Who is funding the study?

The study was founded by the Affiliated Hospital of Qingdao University Medical College and National Natural Sciences Foundation of China.

Who is the main contact?

Prof. Yangang Wang

wangyg1966@126.com

Contact information

Type(s)

Scientific

Contact name

Dr Youxin Wang

Contact details

10 Youanmenwai Xitoutiao

Beijing

China

100069

+86 10 83911497

wangy@ccmu.edu.cn

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Chuanhu anti-gout mixture versus Colchicine for acute gouty arthritis: a randomized, double-blind, double-dummy, non-inferiority trial

Study objectives

Chuanhu anti-gout mixture has been used for many years in Chinese Traditional Medicine (TCM), and may be an effective treatment for acute gouty arthritis.

Ethics approval required

Old ethics approval format

Ethics approval(s)

The study was approved by Qingdao Universitys ethics committee, Nov 1st, 2010

Study design

Randomized double-blind double-dummy non-inferiority trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet Dr. Yunlong Wang, Tel: 0086-13581562524, Email: wylsun@163.com

Health condition(s) or problem(s) studied

Acute gouty arthritis

Interventions

Following screening, eligible patients were randomized (1:1) to two groups:

1. Chuanhu group, to receive Chuanhu anti-gout mixture 250ml orally daily and placebo (looks like colchicine).
2. Colchicine group, to receive Colchicine 1 piece orally (0.5mg per piece), 2 times daily, for 3 days, later change to once daily, and placebo (looks like Chuanhu anti-gout mixture).

All of the patients were treated with etoricoxib 60mg once daily orally to relieve pain of the affected joints for 10 days.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Chuanhu, Colchicine

Primary outcome measure

The recurrence rate within three months of these selected patients after 10 days treatment

Secondary outcome measures

1. The changes of white blood cells and C-reactive protein (CRP).

White blood cells were measured at North West University Nutrition laboratory using an AcT 5diff Cap Pierce Hematology Analyzer, and CRP was measured by immunoturbidimetric test, at the baseline and after 10 days of follow up.

2. Adverse reactions, the score of pain, swelling, and activity limitation of the joint (1-4 point scale, for absent, mild, moderate, or severe, respectively), were recorded in the patient diary, and biochemical indicators were detected.

Overall study start date

01/11/2011

Completion date

01/11/2012

Eligibility

Key inclusion criteria

Adults ≥ 18 year old, either sex, with a new clinical diagnosis of gout according to the 1977 American College of Rheumatology classification criteria and onset of the disease duration less than 48 hours were eligible to participate.

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

176

Total final enrolment

176

Key exclusion criteria

1. Secondary gout, such as rheumatoid arthritis, septic arthritis, traumatic arthritis, etc
2. Gout in intermittent period or with tophi
3. Taking the following drugs: diuretics, pyrazinamide, aspirin, etc
4. Pregnancy, breast-feeding women
5. Cardiovascular and cerebral vascular disease, and severe trauma or underwent surgery
6. Severe infections
7. Hepatobiliary disease or whose ALT and AST were two times higher than upper limit of normal
8. The serum creatinine greater than the upper limit of normal
9. Severe chronic gastrointestinal disease
10. Hematological diseases or endocrine system diseases
11. Undergoing cancer treatment
12. Receiving steroid therapy
13. Allergic to those known ingredients in Chuanhu anti-gout mixture.

Date of first enrolment

01/11/2011

Date of final enrolment

01/11/2012

Locations

Countries of recruitment

China

Study participating centre

10 Youanmenwai Xitoutiao

Beijing

China

100069

Sponsor information

Organisation

The Affiliated Hospital of Medical College Qingdao University (China)

Sponsor details

c/o Prof. Yangang Wang

Department of Endocrinology

16 Jiangsu Road

Qingdao

China

266003

+86 532 82911399

wylapollo@163.com

Sponsor type

Hospital/treatment centre

ROR

<https://ror.org/026e9yy16>

Funder(s)

Funder type

Hospital/treatment centre

Funder Name

Affiliated Hospital of Qingdao University Medical College (China)

Funder Name

The study was in part supported by National Natural Science Foundation of China (81001281)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	14/06/2014	17/12/2020	Yes	No